Abstract
Kinases, which number > 500 in humans, are a class of enzymes that participate in an array of important functions within normal cellular physiology and during various pathological conditions. Due to the key role of kinases in the regulation of all aspects of cellular signaling and the well established contribution of kinase dysregulation to the etiology of many human pathologies, the development of kinase inhibitors has emerged as a therapeutic strategy for the treatment of human disease, including most notably oncology. Difficulties generating selective inhibitors have hampered their use in other therapeutic areas with less tolerance for off-target effects. However, with an increasing understanding of kinase structures and with the advent of newer inhibitor design strategies more highly selective inhibitors are beginning to emerge. This has prompted interest in utilizing kinase inhibitors in therapeutic areas beyond oncology, including acute and chronic neurodegenerative conditions for which disease modify therapies are lacking. This review provides a background in acute (i.e. brain ischemia and traumatic brain injury) and chronic (i.e. Alzheimers, Parkinsons, Huntingtons disease, amyotrophic lateral sclerosis and multiple sclerosis) neurodegenerative conditions. Then, the role of several kinase (i.e. JNK3, p38 MAPK, ERK, PKCδ, ROCKII, GSK3, Cdk5, MLK, EphB3 kinase, RIP1 kinase, LRRK2, TTBK1, ASK1, CK, DAPK, and PKN1) that could serve as potential therapeutic targets for these maladies are reviewed.
Keywords: Kinase, inhibitor, phosphorylation, neurodegeneration, selectivity
Current Pharmaceutical Design
Title: Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Volume: 15 Issue: 34
Author(s): G. D. Cuny
Affiliation:
Keywords: Kinase, inhibitor, phosphorylation, neurodegeneration, selectivity
Abstract: Kinases, which number > 500 in humans, are a class of enzymes that participate in an array of important functions within normal cellular physiology and during various pathological conditions. Due to the key role of kinases in the regulation of all aspects of cellular signaling and the well established contribution of kinase dysregulation to the etiology of many human pathologies, the development of kinase inhibitors has emerged as a therapeutic strategy for the treatment of human disease, including most notably oncology. Difficulties generating selective inhibitors have hampered their use in other therapeutic areas with less tolerance for off-target effects. However, with an increasing understanding of kinase structures and with the advent of newer inhibitor design strategies more highly selective inhibitors are beginning to emerge. This has prompted interest in utilizing kinase inhibitors in therapeutic areas beyond oncology, including acute and chronic neurodegenerative conditions for which disease modify therapies are lacking. This review provides a background in acute (i.e. brain ischemia and traumatic brain injury) and chronic (i.e. Alzheimers, Parkinsons, Huntingtons disease, amyotrophic lateral sclerosis and multiple sclerosis) neurodegenerative conditions. Then, the role of several kinase (i.e. JNK3, p38 MAPK, ERK, PKCδ, ROCKII, GSK3, Cdk5, MLK, EphB3 kinase, RIP1 kinase, LRRK2, TTBK1, ASK1, CK, DAPK, and PKN1) that could serve as potential therapeutic targets for these maladies are reviewed.
Export Options
About this article
Cite this article as:
Cuny D. G., Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions, Current Pharmaceutical Design 2009; 15 (34) . https://dx.doi.org/10.2174/138161209789649330
DOI https://dx.doi.org/10.2174/138161209789649330 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Central Nervous System Agents in Medicinal Chemistry Inflammatory Cyclooxygenase Activity and PGE<sub>2</sub> Signaling in Models of Alzheimer’s Disease
Current Immunology Reviews (Discontinued) Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine
CNS & Neurological Disorders - Drug Targets The Translocator Protein 18 kDa (TSPO) and Its Role in Mitochondrial Biology and Psychiatric Disorders
Mini-Reviews in Medicinal Chemistry Lipoic Acid, a Lead Structure for Multi-Target-Directed Drugs for Neurodegeneration
Mini-Reviews in Medicinal Chemistry Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Density Functional Theory Study of Antioxidant Adsorption onto Single- Wall Boron Nitride Nanotubes: Design of New Antioxidant Delivery Systems
Combinatorial Chemistry & High Throughput Screening Biomarker Discovery and Translation in Metabolomics
Current Metabolomics Cell Death and Apoptosis in Ostearthritic Cartilage
Current Drug Targets Transplantation of Stem Cells as a Potential Therapeutic Strategy in Neurodegenerative Disorders
Current Stem Cell Research & Therapy Recent Advances in the Treatment of Amyotrophic Lateral Sclerosis. Emphasis on Kynurenine Pathway Inhibitors
Central Nervous System Agents in Medicinal Chemistry Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research Experimental Developments and Review of Recent Patents for the Repair of Skeletal Muscles by Methods of Regenerative Medicine
Recent Patents on Regenerative Medicine Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets